Ulcerative Colitis — Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Citation(s)
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis